The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 801 Mounjaro articles
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
With nearly 100 million Indians overweight or obese, Eli Lilly is ramping up access to its game-changing drug Mounjaro across the country. President Winslow Tucker emphasizes responsible use under medical supervision amid rising demand for GLP-1 therapies. This move signals a shift in tackling obesity as a serious disease linked to heart complications.
Following up on real mom experiences with GLP-1 medications, dietician Diana Reid reveals the hidden pitfalls beyond the 'magic wand' hype. From the beach ball metaphor for body set points to essential protein and strength training, learn how to support your body properly. This balanced guide covers benefits like reduced food noise and risks like hair thinning for informed decisions.
Ozempic and metformin are both widely used for Type 2 diabetes management, sharing benefits like blood sugar control and potential weight loss effects, but recent side effect warnings highlight their overlaps and differences. While metformin serves 120 million people worldwide as a daily tablet, Ozempic is a weekly injection for adults. Understand why consulting your doctor is essential before switching.
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
The UK's MHRA has issued a critical warning about counterfeit Mounjaro pens following reports from Eli Lilly. These fake pens contain tirzepatide but may not be sterile, posing potential health risks. Patients are urged to verify batch numbers and report suspicions to the Yellow Card scheme.
Just as smartphones propelled Ireland's economy post-financial crisis, GLP-1 weight-loss drugs like Eli Lilly's Mounjaro and Zepbound are set to do the same. With factories in Kinsale and Limerick producing key ingredients, Ireland eyes massive tax windfalls and export spikes. Gallup data shows US obesity falling to 37%, crediting these therapies.
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
Comedian Tanmay Bhat recently opened up about his disappointing experience with GLP-1 medications, reporting zero appetite suppression despite using them for weight management. He attributes this to a BDNF gene variant affecting satiety signaling, sparking discussions on genetic factors in treatment response. While many see benefits from drugs like semaglutide and tirzepatide, Bhat's story highlights why results vary.
